Loading clinical trials...
Loading clinical trials...
A Phase 1, Randomized, Double-blind, Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending, Multiple Oral Doses of SPD489 (Lisdexamfetamine Dimesylate) in Clinically Stable Adults With Schizophrenia
This is a multiple ascending dose study; the purpose of this study is to examine the safety, tolerability and pharmacokinetics (levels of drug in the blood) of SPD489 in Schizophrenic Patients who are currently maintained on a stable dose of an antipsychotic medication.
Age
18 - 65 years
Sex
ALL
Healthy Volunteers
No
California Clinical Trials
Glendale, California, United States
Collaborative Neuroscience Network, Inc
Long Beach, California, United States
Start Date
October 21, 2011
Primary Completion Date
January 20, 2012
Completion Date
January 20, 2012
Last Updated
June 3, 2021
31
ACTUAL participants
SPD489 (Lisdexamfetamine dimesylate)
DRUG
Placebo
DRUG
Lead Sponsor
Shire
NCT07455929
NCT06740383
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions